Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)		Sep. 30, 2020		Dec. 31, 2019
Humabs | Clinical and Regulatory Milestones | Measurement Input, Discount Rate | Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value contingent consideration measurement input		0.10	[1]	0.077
Humabs | Clinical and Regulatory Milestones | Measurement Input, Discount Rate | Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value contingent consideration measurement input		0.12	[1]	0.111
Humabs | Clinical and Regulatory Milestones | Measurement Input, Discount Rate | Weighted Average
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value contingent consideration measurement input	[1]	0.10
Humabs | Clinical and Regulatory Milestones | Probability of Achievement | Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value contingent consideration measurement input	[1]	0.14
Humabs | Clinical and Regulatory Milestones | Probability of Achievement | Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value contingent consideration measurement input	[1]	1.00
Humabs | Clinical and Regulatory Milestones | Probability of Achievement | Weighted Average
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value contingent consideration measurement input	[1]	0.56
Humabs | Commercial Milestones | Measurement Input, Discount Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value contingent consideration measurement input		0.11	[2]	0.13
Humabs | Commercial Milestones | Probability of Achievement | Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value contingent consideration measurement input	[2]	0.14
Humabs | Commercial Milestones | Probability of Achievement | Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value contingent consideration measurement input	[2]	0.32
Humabs | Commercial Milestones | Probability of Achievement | Weighted Average
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value contingent consideration measurement input	[2]	0.30
Humabs | Commercial Milestones | Measurement Input Expected Revenue Volatility
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value contingent consideration measurement input		0.60	[2]	0.55
TomegaVax | Measurement Input, Discount Rate | Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value contingent consideration measurement input	[3]	0.000
TomegaVax | Measurement Input, Discount Rate | Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value contingent consideration measurement input	[3]	0.002
TomegaVax | Measurement Input, Discount Rate | Weighted Average
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value contingent consideration measurement input	[3]	0.001
TomegaVax | Expected Stock Price Volatility
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value contingent consideration measurement input	[3]	0.85

[1] Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.

[2] Unobservable inputs were weighted based on the relative fair value of the commercial milestone payments

[3] Unobservable inputs were weighted based on the relative fair value of the underlying milestones.